Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tachycardia, Ventricular | 13 | 2024 | 118 | 5.100 |
Why?
|
| Genetic Therapy | 27 | 2024 | 744 | 4.500 |
Why?
|
| Atrial Fibrillation | 19 | 2024 | 805 | 3.780 |
Why?
|
| Arrhythmias, Cardiac | 14 | 2024 | 143 | 2.990 |
Why?
|
| Myocardial Infarction | 9 | 2024 | 869 | 2.760 |
Why?
|
| Gene Transfer Techniques | 19 | 2024 | 307 | 2.750 |
Why?
|
| Long QT Syndrome | 6 | 2023 | 30 | 1.910 |
Why?
|
| Genetic Vectors | 14 | 2024 | 820 | 1.670 |
Why?
|
| Swine | 16 | 2023 | 349 | 1.420 |
Why?
|
| Heart Failure | 7 | 2022 | 869 | 1.420 |
Why?
|
| Heart Atria | 9 | 2024 | 138 | 1.330 |
Why?
|
| Cicatrix | 5 | 2024 | 58 | 1.320 |
Why?
|
| Connexin 43 | 3 | 2015 | 14 | 1.300 |
Why?
|
| Myocardium | 12 | 2023 | 263 | 1.240 |
Why?
|
| Heart Arrest | 4 | 2024 | 161 | 1.100 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2023 | 253 | 1.080 |
Why?
|
| Catheter Ablation | 6 | 2022 | 141 | 1.030 |
Why?
|
| Electrocardiography | 11 | 2024 | 529 | 1.020 |
Why?
|
| Animals | 40 | 2024 | 19769 | 0.980 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 120 | 0.950 |
Why?
|
| Metaplasia | 1 | 2024 | 18 | 0.920 |
Why?
|
| Heart Conduction System | 8 | 2014 | 49 | 0.890 |
Why?
|
| Adenoviridae | 11 | 2010 | 120 | 0.840 |
Why?
|
| Atrial Remodeling | 2 | 2020 | 17 | 0.800 |
Why?
|
| Disease Models, Animal | 8 | 2022 | 2081 | 0.800 |
Why?
|
| Heart | 5 | 2004 | 276 | 0.770 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2019 | 30 | 0.720 |
Why?
|
| Defibrillators, Implantable | 6 | 2010 | 258 | 0.710 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 3 | 2010 | 7 | 0.710 |
Why?
|
| Heart Rate | 7 | 2023 | 308 | 0.700 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2010 | 354 | 0.690 |
Why?
|
| Myocytes, Cardiac | 3 | 2017 | 88 | 0.690 |
Why?
|
| Humans | 44 | 2024 | 60165 | 0.660 |
Why?
|
| Heart Diseases | 1 | 2022 | 206 | 0.650 |
Why?
|
| ERG1 Potassium Channel | 5 | 2023 | 6 | 0.590 |
Why?
|
| Parvovirinae | 1 | 2017 | 3 | 0.590 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2017 | 14 | 0.580 |
Why?
|
| Epigenomics | 1 | 2018 | 55 | 0.570 |
Why?
|
| Viral Tropism | 1 | 2017 | 55 | 0.550 |
Why?
|
| Gene Editing | 1 | 2020 | 301 | 0.520 |
Why?
|
| Potassium Channels, Voltage-Gated | 3 | 2022 | 31 | 0.520 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 470 | 0.520 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 275 | 0.520 |
Why?
|
| Biological Therapy | 1 | 2016 | 16 | 0.510 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 233 | 0.510 |
Why?
|
| Calcium | 3 | 2016 | 560 | 0.480 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 832 | 0.480 |
Why?
|
| Up-Regulation | 2 | 2016 | 365 | 0.480 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 3 | 2004 | 15 | 0.470 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 5 | 2022 | 23 | 0.450 |
Why?
|
| Peptides | 1 | 2017 | 550 | 0.450 |
Why?
|
| Stress, Physiological | 1 | 2015 | 186 | 0.440 |
Why?
|
| Cardiac Pacing, Artificial | 7 | 2011 | 34 | 0.420 |
Why?
|
| Atrial Function, Left | 3 | 2020 | 31 | 0.410 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2004 | 317 | 0.410 |
Why?
|
| Connexins | 1 | 2011 | 10 | 0.390 |
Why?
|
| Perfusion | 3 | 2003 | 77 | 0.390 |
Why?
|
| Rabbits | 6 | 2023 | 329 | 0.380 |
Why?
|
| Heart Ventricles | 3 | 2022 | 251 | 0.360 |
Why?
|
| Action Potentials | 6 | 2015 | 103 | 0.360 |
Why?
|
| Myocardial Contraction | 3 | 2006 | 83 | 0.320 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 149 | 0.320 |
Why?
|
| Time Factors | 8 | 2016 | 3623 | 0.320 |
Why?
|
| Models, Animal | 2 | 2010 | 222 | 0.290 |
Why?
|
| Risk Factors | 6 | 2023 | 5091 | 0.280 |
Why?
|
| Gene Targeting | 1 | 2007 | 82 | 0.270 |
Why?
|
| Treatment Outcome | 9 | 2016 | 5267 | 0.260 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 21 | 0.260 |
Why?
|
| Atrioventricular Node | 3 | 2004 | 9 | 0.260 |
Why?
|
| Cyclic GMP | 2 | 2007 | 28 | 0.250 |
Why?
|
| Staphylococcal Infections | 1 | 2006 | 116 | 0.230 |
Why?
|
| Cell Communication | 1 | 2005 | 127 | 0.230 |
Why?
|
| Lipomatosis | 1 | 2024 | 8 | 0.230 |
Why?
|
| Sus scrofa | 4 | 2017 | 27 | 0.230 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2004 | 46 | 0.220 |
Why?
|
| Guinea Pigs | 2 | 2022 | 103 | 0.210 |
Why?
|
| Tissue Distribution | 1 | 2023 | 286 | 0.200 |
Why?
|
| Risk Assessment | 3 | 2023 | 1937 | 0.200 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2022 | 16 | 0.200 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2017 | 497 | 0.190 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2016 | 93 | 0.190 |
Why?
|
| Echocardiography | 3 | 2020 | 460 | 0.190 |
Why?
|
| MicroRNAs | 2 | 2020 | 620 | 0.190 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2001 | 3 | 0.190 |
Why?
|
| Adenoviruses, Human | 1 | 2001 | 9 | 0.190 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 25 | 0.180 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 21 | 0.180 |
Why?
|
| Lymphokines | 1 | 2001 | 66 | 0.180 |
Why?
|
| Electrophysiology | 3 | 2008 | 89 | 0.180 |
Why?
|
| Transfection | 3 | 2015 | 676 | 0.180 |
Why?
|
| Male | 12 | 2022 | 27985 | 0.170 |
Why?
|
| Mutation | 4 | 2015 | 2474 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2016 | 52 | 0.160 |
Why?
|
| Telemetry | 1 | 2019 | 21 | 0.160 |
Why?
|
| Female | 11 | 2022 | 31256 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 509 | 0.150 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 5 | 0.150 |
Why?
|
| Serotonin | 1 | 1998 | 63 | 0.150 |
Why?
|
| Virus Attachment | 1 | 2017 | 23 | 0.140 |
Why?
|
| Bradycardia | 2 | 2010 | 34 | 0.140 |
Why?
|
| Syncope | 2 | 2010 | 42 | 0.140 |
Why?
|
| Virulence | 1 | 2017 | 187 | 0.140 |
Why?
|
| Middle Aged | 7 | 2024 | 16554 | 0.140 |
Why?
|
| Genes, Viral | 1 | 1997 | 56 | 0.140 |
Why?
|
| Signal Transduction | 2 | 2019 | 2893 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2017 | 127 | 0.140 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2102 | 0.140 |
Why?
|
| Capsid Proteins | 1 | 2017 | 93 | 0.140 |
Why?
|
| Electric Countershock | 2 | 2010 | 98 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 155 | 0.130 |
Why?
|
| Genes, Reporter | 3 | 2005 | 244 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2023 | 1175 | 0.130 |
Why?
|
| Voltage-Sensitive Dye Imaging | 1 | 2015 | 1 | 0.130 |
Why?
|
| Dependovirus | 2 | 2017 | 659 | 0.130 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 36 | 0.130 |
Why?
|
| Random Allocation | 2 | 2014 | 197 | 0.130 |
Why?
|
| Serine | 1 | 2015 | 83 | 0.120 |
Why?
|
| Animals, Newborn | 1 | 2015 | 230 | 0.120 |
Why?
|
| GTP-Binding Protein alpha Subunit, Gi2 | 3 | 2004 | 5 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 354 | 0.120 |
Why?
|
| Aged | 8 | 2020 | 13601 | 0.120 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2014 | 37 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 570 | 0.110 |
Why?
|
| Phosphorylation | 1 | 2015 | 861 | 0.110 |
Why?
|
| Cell Line | 1 | 2017 | 2019 | 0.100 |
Why?
|
| beta-Galactosidase | 2 | 2005 | 81 | 0.100 |
Why?
|
| Choroidal Neovascularization | 1 | 2013 | 29 | 0.100 |
Why?
|
| Stilbenes | 1 | 2013 | 46 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 78 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 157 | 0.100 |
Why?
|
| Sick Sinus Syndrome | 1 | 2011 | 4 | 0.100 |
Why?
|
| Sinoatrial Node | 1 | 2011 | 3 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 679 | 0.090 |
Why?
|
| Macular Degeneration | 1 | 2013 | 179 | 0.090 |
Why?
|
| Oxygen | 1 | 2011 | 309 | 0.080 |
Why?
|
| Phenotype | 2 | 2010 | 1158 | 0.080 |
Why?
|
| Tachycardia | 1 | 2008 | 28 | 0.080 |
Why?
|
| Genotype | 1 | 2010 | 643 | 0.070 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 220 | 0.070 |
Why?
|
| Channelopathies | 1 | 2007 | 5 | 0.070 |
Why?
|
| Wound Healing | 1 | 2008 | 177 | 0.070 |
Why?
|
| Biomarkers | 3 | 2020 | 1215 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 2049 | 0.070 |
Why?
|
| Endocardium | 1 | 2006 | 12 | 0.070 |
Why?
|
| Thrombomodulin | 1 | 2006 | 16 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2020 | 2481 | 0.070 |
Why?
|
| Adenosine | 1 | 2007 | 69 | 0.070 |
Why?
|
| Coronary Vessels | 1 | 2007 | 109 | 0.060 |
Why?
|
| Stroke Volume | 2 | 2005 | 323 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2007 | 144 | 0.060 |
Why?
|
| Equipment Safety | 1 | 2005 | 21 | 0.060 |
Why?
|
| Trypsin | 1 | 2005 | 41 | 0.060 |
Why?
|
| Poloxamer | 1 | 2005 | 13 | 0.060 |
Why?
|
| Tensile Strength | 1 | 2005 | 28 | 0.060 |
Why?
|
| Diltiazem | 1 | 2004 | 3 | 0.060 |
Why?
|
| Propanolamines | 1 | 2004 | 10 | 0.060 |
Why?
|
| Digoxin | 1 | 2004 | 17 | 0.060 |
Why?
|
| Pericardium | 1 | 2005 | 35 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 161 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 102 | 0.060 |
Why?
|
| Femoral Vein | 1 | 2004 | 15 | 0.060 |
Why?
|
| Calcium Channels, L-Type | 1 | 2004 | 25 | 0.060 |
Why?
|
| Recurrence | 2 | 2016 | 600 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 44 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 56 | 0.060 |
Why?
|
| Potassium Channel Blockers | 1 | 2004 | 25 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2006 | 522 | 0.060 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2004 | 37 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 793 | 0.050 |
Why?
|
| Apoptosis | 2 | 2011 | 1042 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1543 | 0.050 |
Why?
|
| Fibrosis | 1 | 2004 | 152 | 0.050 |
Why?
|
| Sex Factors | 1 | 2006 | 971 | 0.050 |
Why?
|
| Aging | 1 | 2009 | 731 | 0.050 |
Why?
|
| Problem-Based Learning | 1 | 2003 | 35 | 0.050 |
Why?
|
| Solutions | 1 | 2003 | 61 | 0.050 |
Why?
|
| Acute Disease | 1 | 2004 | 661 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2002 | 29 | 0.050 |
Why?
|
| Rats | 2 | 2006 | 1915 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 48 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2004 | 460 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2002 | 61 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2003 | 124 | 0.050 |
Why?
|
| Purinones | 1 | 2001 | 1 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2001 | 5 | 0.050 |
Why?
|
| Guanylate Cyclase | 1 | 2001 | 8 | 0.050 |
Why?
|
| omega-N-Methylarginine | 1 | 2001 | 8 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2001 | 9 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 21 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2001 | 12 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2003 | 159 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 46 | 0.050 |
Why?
|
| Sulfones | 1 | 2001 | 37 | 0.050 |
Why?
|
| Purines | 1 | 2001 | 38 | 0.050 |
Why?
|
| Transformation, Genetic | 1 | 2000 | 27 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2001 | 31 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 5205 | 0.050 |
Why?
|
| Electric Conductivity | 1 | 2000 | 52 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2001 | 133 | 0.040 |
Why?
|
| Piperazines | 1 | 2001 | 81 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 2363 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2020 | 122 | 0.040 |
Why?
|
| Pyridines | 1 | 2001 | 98 | 0.040 |
Why?
|
| Adult | 4 | 2015 | 15989 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 201 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2014 | 179 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1998 | 11 | 0.040 |
Why?
|
| Bradykinin | 1 | 1998 | 8 | 0.040 |
Why?
|
| Permeability | 1 | 1998 | 49 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 3131 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 1998 | 50 | 0.040 |
Why?
|
| Lac Operon | 1 | 1997 | 26 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 1998 | 472 | 0.040 |
Why?
|
| Luciferases | 1 | 1997 | 109 | 0.030 |
Why?
|
| Mice | 2 | 2011 | 10340 | 0.030 |
Why?
|
| Dogs | 2 | 2011 | 312 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1239 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 125 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 260 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 61 | 0.030 |
Why?
|
| Cryosurgery | 1 | 2015 | 24 | 0.030 |
Why?
|
| Adolescent | 1 | 2006 | 5961 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2014 | 18 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2014 | 22 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 31 | 0.030 |
Why?
|
| Alginates | 1 | 2014 | 44 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2006 | 6150 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 322 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2014 | 131 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1036 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 576 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 811 | 0.030 |
Why?
|
| Fever | 1 | 2013 | 64 | 0.030 |
Why?
|
| Headache | 1 | 2013 | 63 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 170 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1066 | 0.020 |
Why?
|
| Angiotensin II | 1 | 2011 | 24 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 64 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 1592 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 202 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 930 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2007 | 20 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1227 | 0.020 |
Why?
|
| Electrodes | 1 | 2007 | 36 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 603 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2006 | 179 | 0.020 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 2004 | 2 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 2004 | 44 | 0.010 |
Why?
|
| Injections | 1 | 2004 | 79 | 0.010 |
Why?
|
| Phenethylamines | 1 | 2004 | 9 | 0.010 |
Why?
|
| Chromans | 1 | 2004 | 16 | 0.010 |
Why?
|
| Ventricular Function | 1 | 2004 | 21 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 2004 | 50 | 0.010 |
Why?
|
| Heart Block | 1 | 2004 | 23 | 0.010 |
Why?
|
| Health Education | 1 | 2005 | 184 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 257 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2004 | 165 | 0.010 |
Why?
|
| Health Policy | 1 | 2005 | 183 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2004 | 180 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2005 | 342 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2004 | 123 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2004 | 155 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 398 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2002 | 14 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2002 | 14 | 0.010 |
Why?
|
| Isoproterenol | 1 | 2002 | 34 | 0.010 |
Why?
|
| Cell Size | 1 | 2002 | 41 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 176 | 0.010 |
Why?
|
| United States | 1 | 2007 | 7623 | 0.010 |
Why?
|